/ /

  • linkedin
  • Increase Font
  • Sharebar

    Alcon IOP-lowering glaucoma treatment approved in EU


    Basel, Switzerland—Alcon Laboratories’ brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL (Simbrinza) eye drop formulation have been approved by the European Commission to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension.

    The treatment, administered with one drop into the affected eyes twice daily, combines the two therapies of brinzolamide and brimonidine for elevated IOP into one, multidose bottle.

    “(The treatment) complements Alcon’s glaucoma portfolio by addressing a significant unmet patient need,” said Jeff George, global head of Alcon. “We are so pleased to introduce the only fixed-combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition.”

    The launch of the treatment in the European Union will start in the United Kingdom in the third quarter of 2014, followed by other European markets later this year and in 2015. In the United States, the treatment was approved by the FDA and has been available in the market since 2013.

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results